Genprex, which is developing gene-based nanoparticle therapies to treat cancer, announced that it expects to price its IPO in February 2018. The company originally filed an S-1 in 2017 for a "best efforts" offering; Renaissance Capital began tracking the company after it filed a POS AM in December, which modified the IPO to be on a firm commitment basis.
The Austin, TX-based company plans to raise $6.5 million by offering 1.3 million shares at a price of $5. At that price, Genprex would command a fully diluted market value of $75 million.
Genprex was founded in 2009 and plans to list on the Nasdaq under the symbol GNPX. Network 1 Financial Securities is the sole bookrunner on the deal.
